R 835
Alternative Names: R-835Latest Information Update: 28 Sep 2024
At a glance
- Originator Rigel Pharmaceuticals
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors; IRAK4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in USA (PO)
- 03 Aug 2021 Phase-I development in Autoimmune disorders is ongoing in USA
- 28 Jul 2021 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in USA (PO)